Everbright Securities Company Limited(601788)
about
Chengda Pharmaceutical Co., Ltd. initial public offering and listing on the gem
Listing recommendation
Sponsor
January 2002
Shenzhen Stock Exchange:
Chengda Pharmaceutical Co., Ltd. plans to apply for initial public offering and listing on the gem. Everbright Securities Company Limited(601788) considers that the issuer’s application for IPO and listing on the gem fully complies with the relevant provisions of the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of the registration of IPO shares on the gem (for Trial Implementation) and the rules for the listing of shares on the gem of Shenzhen Stock Exchange (revised in December 2020), It is recommended that its shares be listed and traded on your gem.
Statement of recommendation institution and recommendation representative
Everbright Securities Company Limited(601788) and Yang Ke and fan Guozu, the sponsor representatives specifically responsible for this securities issuance project, have been in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of securities issuance and listing sponsorship business, and the measures for the administration of the registration of initial public offering of shares on the gem (for Trial Implementation) The Listing Rules of Shenzhen Stock Exchange gem and other relevant laws and regulations and the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange shall be honest, trustworthy, diligent and responsible, issue this listing recommendation letter in strict accordance with the business rules and industry self-discipline norms formulated according to law, and ensure that the documents issued are true, accurate and complete.
catalogue
The sponsor and its representative declare that 2 catalog 3 interpretation 4 I. Basic information of the issuer 6. II. This offering III. sponsor representatives, CO sponsors and other members of the project team for this securities issuance and listing 14 IV. description of whether the recommendation institution has any circumstances that may affect the fair performance of recommendation duties 17 v. commitments of the sponsor Vi. decision making procedures performed by the issuer in connection with this securities issuance and listing 19 VII. Explanation of the sponsor on whether the company meets the listing conditions 19 VIII. Specific arrangements for the issuer’s continuous supervision after the listing of Securities IX. other matters that the recommendation institution deems necessary to explain X. recommendation conclusion of the recommendation institution on the issuer’s listing of shares twenty-five
interpretation
In this listing recommendation letter, unless the context otherwise requires, the following words or abbreviations have the following meanings: the company, the company, the issuer and Chengda Pharmaceutical Co., Ltd
The listing recommendation letter refers to the Everbright Securities Company Limited(601788) listing recommendation letter on the initial public offering of shares and listing on the gem of Chengda Pharmaceutical Co., Ltd
Chengda Co., Ltd. refers to Zhejiang Jiashan Chengda Pharmaceutical Co., Ltd., which is the predecessor of the issuer
Incyte Corporation, headquartered in the United States, is a biopharmaceutical company engaged in drug research, development and sales of Incyte. Its main treatment fields include tumor, inflammation and autoimmunity
Helsinn refers to helsinn group, a pharmaceutical group headquartered in Switzerland, which focuses on tumor and tumor adjuvant therapy
GileadSciences, Inc., gillid, headquartered in the United States, is a biopharmaceutical company engaged in the development and marketing of Gilead finger products. Its main areas of interest include AIDS, liver diseases, cancer, inflammation and respiratory diseases.
GSK refers to GlaxoSmithKline PLC, GlaxoSmithKline PLC, a global pharmaceutical and health care company headquartered in the UK. Its business mainly covers three fields: prescription drugs, vaccines and consumer health products
Eli Lilly refers to Eli lillyand company, a multinational pharmaceutical company headquartered in the United States. Biochemical medicine is its largest business
The general meeting of shareholders refers to the general meeting of shareholders of Chengda Pharmaceutical Co., Ltd
Board of directors means the board of directors of Chengda Pharmaceutical Co., Ltd
The board of supervisors refers to the board of supervisors of Chengda Pharmaceutical Co., Ltd
CSRC refers to the China Securities Regulatory Commission
Company Law refers to the company law of the people’s Republic of China
Securities Law means the securities law of the people’s Republic of China
The measures for the administration of registration refer to the measures for the administration of the registration of initial public offerings on the gem (for Trial Implementation)
Listing Rules refer to Shenzhen Stock Exchange GEM Listing Rules (revised in December 2020)
This offering refers to the issuer’s public offering of A-Shares to the public
A share refers to ordinary shares with a par value of RMB 1.00 per share
Sponsor, recommendation institution, main contractor Everbright Securities Company Limited(601788) distributor, Everbright Securities Company Limited(601788) accounting firm and auditor refer to Zhonghua accounting firm (special general partnership), formerly known as Shanghai Zhonghua Shanghai structure and zhonghuayin accounting firm
Lawyer of the issuer refers to Beijing zhonglunwende law firm
The reporting period, the last three years and the first period refer to 2018, 2019, 2020 and January June 2021
Yuan means RMB yuan
Ten thousand yuan means ten thousand yuan
Special note: in this listing recommendation letter, if there is any difference in the mantissa between the sum of some total numbers and each addend, it is caused by rounding in the calculation.
1、 Basic information of the issuer (I) overview of the issuer
Company name: Chengda Pharmaceutical Co., Ltd
English Name: Chengda Pharmaceuticals Co., Ltd
The registered capital is 72.522105 million yuan
Legal representative: Ge Jianli
Date of establishment of the company: March 25, 1999
Date of establishment of the joint stock company: December 9, 2009
Company domicile: No. 36, Huanghe Road, Huimin street, Jiashan County, Jiaxing City, Zhejiang Province
Postal Code: 314100
Tel.: 0573-84601188
Fax: 0573-84185902
E-mail [email protected].
Company website http://www.chengdapharm.com./
Department responsible for information disclosure and investor relations Securities Department
Person in charge of information disclosure Yang Xiaojing
Telephone number of the person in charge of information disclosure: 0573-84185902
(II) main business of the issuer
The company is mainly committed to providing cdmo services for key pharmaceutical intermediates for multinational pharmaceutical enterprises and pharmaceutical R & D institutions, and engaged in the R & D, production and sales of L-carnitine series products. Since its establishment, the company has adhered to the field of pharmaceutical cdmo and provided customers with services such as process R & D and optimization, quality research and customized production of key pharmaceutical intermediates in the stage of drug clinical trial and commercialization. After more than 20 years of accumulation, the terminal drugs used by the company involve many fields of treatment, such as anti tumor, AIDS, hepatitis B, hepatitis C, myelofibrosis, epilepsy, Parkinson’s disease and so on. Terminal customization customers served by the company include multinational pharmaceutical enterprises such as Incyte, Helsin, Lilly / Evonik, Gilead and GSK. In terms of L-carnitine series products, the company is one of the main suppliers of L-carnitine series products in the world. Its products are exported to more than 30 countries around the world and have strong market competitiveness.
(III) core technology and R & D level of the issuer
The company is a high-tech enterprise, with provincial high-tech enterprise research and development center, provincial enterprise technology center and Zhejiang postdoctoral workstation. Since its establishment, the company has always attached great importance to the R & D and technological innovation of new products and processes, and established a market-oriented R & D management system. Through continuous R & D and innovation, the company’s products have won a number of national and provincial scientific research achievements and honors, such as “national key new products”, “national torch plan project”, “R & D project of the Ministry of Commerce” and so on.
The company has long focused on the field of chemical synthesis and preparation. After years of unremitting independent innovation and R & D, the company has accumulated a number of core technologies, such as water-soluble small molecule amino acid separation and purification technology, drug chiral synthesis technology, transition metal catalyzed coupling reaction technology, diversified chemical synthesis production technology, equipment and device transformation technology in line with the implementation of industrialization. The company is committed to applying the core technology and production process to the process development and production process of various products. “Separation and purification technology of water-soluble small molecular amino acids” means that the company applies electrochemical membrane separation technology to the production of water-soluble amino acids, successfully realizes the efficient separation of target compounds and inorganic salt impurities, and then lays a foundation for large-scale production. “Drug chiral synthesis technology” refers to the company’s successful use of chiral synthesis technology to develop many products, skillfully design new synthesis routes in the process of process research and development, use cheap raw materials to replace expensive raw materials as much as possible, and avoid problems such as too many side reactions and chiral center racemization due to reaction conditions High quality chiral compounds were obtained by chiral source synthesis and chiral resolution. “Transition metal catalyzed coupling reaction technology” means that the company has skillfully developed transition metal catalysts and ligands suitable for different substrates through continuous exploration and attempt, and realized the efficient synthesis of a series of products. “Diversified chemical synthesis production technology” and “equipment and device transformation technology in line with the implementation of industrialization” mean that the company has mastered the synthesis technologies and means with certain difficulties, such as high temperature and high pressure reaction, anhydrous anaerobic reaction and ultra-low temperature reaction, and can design manufacturing devices that meet the actual process requirements according to specific reaction types, so as to break through the bottleneck of process technology, It meets the diversified needs of product development and production, and provides technical guarantee for the smooth implementation of industrialization. (IV) main operating and financial data and indicators of the issuer
Project 2021.6.30/ 2020.12.31 / 2019.12.31 / 2018.12.31 / January June 2021 2020 2019 2018
Total assets (10000 yuan) 59745.11 53420.67 54656.17 44453.10
Owner’s equity attributable to the parent company (10000 yuan) 47937.03 45806.29 35614.37 27952.32
Asset liability ratio (parent company) 19.60%, 14.07%, 34.69%, 37.12%
Project 2021.6.30/ 2020.12.31 / 2019.12.31 / 2018.12.31 / January June 2021 2020 2019 2018
Operating income (10000 yuan) 19515.17 37303.69 29397.29 20317.46
Net profit (10000 yuan) 5086.96 11960.84 5418.49 671.01
Net profit attributable to the owner of the parent company (10000 yuan) 5093.49 12117.42 5422.39 671.01
deduction
